Last reviewed · How we verify
Placebo SLIT-tablet — Competitive Intelligence Brief
phase 3
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo SLIT-tablet (Placebo SLIT-tablet) — ALK-Abelló A/S. A placebo sublingual immunotherapy tablet designed to assess efficacy and safety in phase 3 trials by delivering no active therapeutic agent.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo SLIT-tablet TARGET | Placebo SLIT-tablet | ALK-Abelló A/S | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo SLIT-tablet CI watch — RSS
- Placebo SLIT-tablet CI watch — Atom
- Placebo SLIT-tablet CI watch — JSON
- Placebo SLIT-tablet alone — RSS
Cite this brief
Drug Landscape (2026). Placebo SLIT-tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-slit-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing